


PHARMACEUTICAL 2022

NeuroBo Pharmaceuticals Inc. Rank 418 of 475







PHARMACEUTICAL 2022

## NeuroBo Pharmaceuticals Inc. Rank 418 of 475

The relative strengths and weaknesses of NeuroBo Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NeuroBo Pharmaceuticals Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 46% points. The greatest weakness of NeuroBo Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 316% points.

The company's Economic Capital Ratio, given in the ranking table, is -484%, being 208% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	16,584
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,157
Liabilities, Non-Current	45
Other Assets	105
Other Compr. Net Income	-10
Other Expenses	0
Other Liabilities	0
Other Net Income	14
Property and Equipment	110
Research and Development	6,546
Revenues	0
Selling, General and Administrative Expense	8,752

Output Variable	Value in 1000 USD
Assets	16,799
Liabilities	2,202
Expenses	15,298
Stockholders Equity	14,597
Net Income	-15,284
Comprehensive Net Income	-15,289
Economic Capital Ratio	-484%

